ABSTRACT. The aim of this study was to explore whether estrogen receptor 1 (ESR1) PvuII and XbaI polymorphisms are associated with susceptibility to Alzheimer's disease (AD). We conducted a metaanalysis of the associations between AD and ESR1 PvuII and XbaI polymorphisms as well as haplotypes of the ESR1 PvuII and XbaI polymorphisms. A total of 1359 patients and 1387 controls from 9 studies on the ESR1 PvuII polymorphism and 1525 patients and 1575 controls from 8 studies on the ESR1 XbaI polymorphism were included in this meta-analysis. Gender-specific meta-analysis showed an association between the ESR1 PP+Pp genotype and AD in males (OR = 0.302, 95%CI = 0.100-0.914, P = 0.034), but not in females. No association was observed between AD and the ESR1 XbaI X allele (OR = 1.114, 95%CI = 0.868-1.429, P = 0.397). However, country-specific meta-analysis identified an association between AD and the ESR1 X allele in Japanese (OR = 1.386, 95%CI = 1.055-1.822, P = 0.019), but not Chinese or Italian populations. Meta-analyses results indicated an association between the PP/XX haplotypes and AD in Chinese ). This meta-analysis showed associations between the ESR1 PvuII polymorphism and AD susceptibility in males, between AD risk and the ESR1 XbaI polymorphism in the Japanese population, and between the PP/XX haplotype and AD susceptibility in the Chinese population.
ABSTRACT. The aim of this study was to explore whether estrogen receptor 1 (ESR1) PvuII and XbaI polymorphisms are associated with susceptibility to Alzheimer's disease (AD). We conducted a metaanalysis of the associations between AD and ESR1 PvuII and XbaI polymorphisms as well as haplotypes of the ESR1 PvuII and XbaI polymorphisms. A total of 1359 patients and 1387 controls from 9 studies on the ESR1 PvuII polymorphism and 1525 patients and 1575 controls from 8 studies on the ESR1 XbaI polymorphism were included in this meta-analysis. Gender-specific meta-analysis showed an association between the ESR1 PP+Pp genotype and AD in males (OR = 0.302, 95%CI = 0.100-0.914, P = 0.034), but not in females. No association was observed between AD and the ESR1 XbaI X allele (OR = 1.114, 95%CI = 0.868-1.429, P = 0.397). However, country-specific meta-analysis identified an association between AD and the ESR1 X allele in Japanese (OR = 1.386, 95%CI = 1.055-1.822, P = 0.019), but not Chinese or Italian populations. Meta-analyses results indicated an association between the PP/XX haplotypes and AD in Chinese
INTRODUCTION
Alzheimer's disease (AD) is a complex, progressive, and irreversible neurodegenerative disease of the brain. AD is characterized by the accumulation of the amyloid-b (Ab) protein and neurofibrillary tangles in the brain (Boada et al., 2012a) . Although the etiology of AD has not been determined, a genetic component of susceptibility to AD has been established by some case-control, twin, and family studies.
Estrogen induces synaptogenesis, acts as a neuroprotective agent, regulates neurotransmission in the central nervous system (CNS), and is associated with cognitive symptoms (Szego et al., 2011) . Estrogen may inhibit the formation of the Ab protein and protect against Ab protein-induced neuronal death (Szego et al., 2011) , however AD may be more prevalent in women, attributed in part, to estrogen (Bachman et al., 1992) . Thus estrogen is considered to play a role in the pathogenesis of AD (Xing et al., 2013) . Estrogen action is mediated through estrogen receptors 1 (ESR1) and 2 (ESR2). The ESR1 gene, located on chromosome 6q25.1, is expressed in the brain, predominantly in the hypothalamus and amygdale (Xing et al., 2013) . ESR1 polymorphisms located in intron 1, PvuII (rs2234693) and XbaI (rs9340799), may be in linkage disequilibrium (LD) with regulatory polymorphisms that affect ESR1 expression or disease susceptibility genes. The ESR1 PvuII and XbaI polymorphisms have been the most intensively studied in association with susceptibility to AD and whether ESR1gene plays a role in the pathogenesis of AD (Xing et al., 2013) .
Published results on the genetic association of ESR1 polymorphisms are controversial and inconclusive. While some reports have shown associations between these ESR1 polymorphisms and AD, others found no such association (Ji et al., 2000; Maruyama et al., 2000; Lambert et al., 2001; Lin et al., 2003; Monastero et al., 2006; Porrello et al., 2006; Usui et al., 2006; Dresner-Pollak et al., 2009; Ma et al., 2009; Boada et al., 2012b; Deng et al., 2013) . This discrepancy may be due to sample size, statistical power, ethnicity, gender, clinical heterogeneity, or a combination of these factors. Meta-analysis is a powerful tool to overcome the drawbacks of small sample size and inadequate statistical power from genetic studies of complex traits. To overcome the limitations of individual studies, we carried out a meta-analysis (Lee and Nath, 2005; Lee et al., , 2006 to determine whether the ESR1 PvuII and XbaI polymorphisms are associated with susceptibility to AD.
METHODS

Identification of eligible studies and data extraction
Using MEDLINE and EMBASE citation databases, we performed a literature search to identify articles published up to October 2013 that examined associations between ESR1 polymorphisms and AD. Combinations of key words such as "estrogen receptor 1", "ESR1", "polymorphism", "Alzheimer's disease", and "AD" were entered as Medical Subject Heading terms and text words. References in the studies identified were used to identify additional studies not indexed by the electronic databases. Inclusion criteria were as follows: 1) case-control study design, 2) original data, 3) genotype or allele data to calculate odds ratios (ORs), and 4) studies in which the genotype distribution in the controls was not consistent with the HardyWeinberg equilibrium (HWE), because such deviations in HWE among controls suggests the possibility of bias during control selection or genotyping errors. The following information was extracted from each study identified: author, year of publication, ethnicity and country of the study population, demographics, and number of cases and controls for each ESR1 polymorphism. Allele frequencies were calculated from the corresponding genotype distributions.
Evaluation of statistical associations
A chi-square test was used to determine whether observed genotype frequencies conformed to HWE. Point estimates of risks, ORs, and 95% confidence intervals (CIs) were estimated for each study. Cochran's Q-statistic was used to assess intra-and inter-study variation or heterogeneity. I 2 values ranged between 0 and 100%, representing the proportion of interstudy variability attributable to heterogeneity rather than chance (Higgins and Thompson, 2002) . I 2 values of 25, 50, and 75% were nominally assigned as low, moderate, and high estimates, respectively. The fixed-effects model assumed that a genetic factor had the same effect on AD susceptibility across all studies investigated and that variations between studies were caused by chance alone. The random-effects model assumed that different studies had substantial diversity and assessed intra-study sampling error and inter-study variance (DerSimonian and Laird, 1986) . A comprehensive meta-analysis program (Biostat Englewood, NJ, USA) was used for analysis. Study power was computed as the probability of detecting an association between the ESR1 polymorphisms and AD at a significance level of 0.05, assuming an OR of 1.5 (small effect size). Power analysis was performed using the G*Power statistical program (http://www.psycho.uni-duesseldorf.de/aap/projects/gpower).
Evaluation of heterogeneity and publication bias
Meta-regression was performed to examine the potential source of heterogeneity observed in the meta-analysis. Sensitivity analysis was also performed to assess the influence of each individual study on the pooled OR by omitting each individual study. We evaluated publication bias using Egger's linear regression test, which measures funnel plot asymmetry using a natural logarithmic scale of ORs. When asymmetry was indicated, we used the trim and fill method to adjust the summary estimate for the bias observed.
RESULTS
Studies included in the meta-analysis
We identified 135 studies by electronic and manual search, of which 16 studies were selected for a full-text review on the basis of the title and abstract details (Isoe-Wada et al., ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 9361-9369 (2015) 1999; Ji et al., 2000; Maruyama et al., 2000; Lambert et al., 2001; Lin et al., 2003; den Heijer et al., 2004; Pirskanen et al., 2005; Monastero et al., 2006; Porrello et al., 2006; Usui et al., 2006; Boccardi et al., 2008; Dresner-Pollak et al., 2009; Ma et al., 2009; Goumidi et al., 2011; Boada et al., 2012b; Deng et al., 2013) . After full-text review, seven studies were excluded, of which 4 did not contain genotype data for ESR1 polymorphism (den Heijer et al., 2004; Pirskanen et al., 2005; Boccardi et al., 2008; Goumidi et al., 2011) , 2 contained data on control genotype deviated from HWE (Maruyama et al., 2000; Boada et al., 2012b) and 1 study contained duplicate data (Isoe-Wada et al., 1999) . Thus, a total of 9 studies (Ji et al., 2000; Lambert et al., 2001; Lin et al., 2003; Monastero et al., 2006; Porrello et al., 2006; Usui et al., 2006; Dresner-Pollak et al., 2009; Ma et al., 2009; Deng et al., 2013) , corresponding to 1359 patients and 1387 controls, met all the inclusion criteria and were considered for the ESR1 XbaI polymorphism meta-analysis (Table  1C) . Of these, 8 studies corresponding to 1525 patients and 1575 controls were also included in the ESR1 PvuII polymorphism meta-analysis (Table 1B) . The statistical power of the studies ranged from 23.6 to 68.1% and none had statistical power exceeding 80%. 
Meta-analysis of the ESR1 PvuII polymorphism and AD
No association was observed between AD and the ESR1 PvuII P allele in the combined study subjects (OR = 1.135, 95%CI = 0.920-1.401, P = 0.238) (Table 2, Figure 1 ). Country-specific meta-analysis indicated no association between the ESR1 P allele and AD in either Chinese (OR = 0.999, 95%CI = 0.700-1.424, P = 0.993) or Japanese (OR = 1.272, 95%CI = 0.823-1.966, P = 0.279) population (Table 2 ). ESR1 polymorphism data in both, males and females, was presented in 2 studies (Lambert et al., 2001; Lin et al., 2003) . Gender-specific meta-analysis of results from these studies indicated no association between the ESR1 P allele and AD in females (OR = 1.496, 95%CI = 0.724-3.091, P = 0.277) or males (OR = 1.187, 95%CI = 0.821-1.716, P = 0.363) ( Table  2 ). However, meta-analysis using dominant model showed an association between the ESR1 PvuII polymorphism and AD in males (OR = 0.302, 95%CI = 0.100-0.914, P = 0.034), but not in females. 
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Meta-analysis of ESR1 XbaI polymorphism and AD
Meta-analysis of the combined study subjects showed no association between AD and the ESR1 XbaI X allele (OR = 1.114, 95%CI = 0.868-1.429, P = 0.397) (Table 3, Figure 2) .
However, country-specific meta-analysis identified an association between AD and the ESR1 XbaI X allele in Japanese (OR = 1.386, 95%CI = 1.055-1.822, P = 0.019), but not in either Chinese or Italian population (Table 3) . Gender-specific meta-analysis indicated no association between the ESR1 X allele and AD in both, males and females (Table 3) .
Meta-analysis of PvuII-XbaI haplotype and AD
Meta-analyses of the PvuII-XbaI haplotype showed a significant association between the PP/XX haplotypes and AD (OR for PP/XX vs others = 1.666, 95%CI = 0.026-2.705, P = 0.039; OR for PP/XX vs pp/xx = 2.071, 95%CI = 1.150-6.368, P = 0.023) ( Table 4) . Countryspecific meta-analysis indicated an association between the PP/XX haplotypes and AD Chinese (OR for PP/XX vs others = 2.758, 95%CI = 1.750-4.346, P = 1.2 x 10 -6 ; OR for PP/XX vs pp/xx = 14.66, 95%CI = 6.729-31.95, P < 1.0 x 10 -8 ), but not in Italian population (Table 4) . Heterogeneity, meta-regression, sensitivity analysis, and publication bias
Inter-study heterogeneity was observed in meta-analyses of the ESR1 PvuII and XbaI polymorphisms and PP/XX haplotypes (Tables 2 and 3 ). Meta-regression showed that sample size (P = 0.013), but not ethnicity (P = 0.534), and publication year (P = 0.162) had a significant impact on the heterogeneity in the ESR1 PvuII polymorphism. Sensitivity analysis showed that no individual study significantly affected the pooled OR. Egger's regression test showed evidence of publication bias in the meta-analyses of the ESR1 PvuII and XbaI polymorphisms (Egger's regression test P values = 0.085, 0.017). However, the adjusted ORs by the trim and fill technique were not significantly changed.
DISCUSSION
In the present study, we conducted a country-and gender-specific meta-analyses of the associations between the ESR1 PvuII and XbaI polymorphisms and AD susceptibility. We found an association between the ESR1 PvuII polymorphism and AD susceptibility in males, and an association between AD risk and the ESR1 XbaI polymorphism in the Japanese population. We also detected an association between the PP/XX haplotype of the ESR1 PvuII and XbaI polymorphisms and AD susceptibility in the Chinese population.
ESR1 polymorphisms may have a functional significance. Maruyama et al. (2000) found that ESR1 PvuII and XbaI polymorphisms showed a weak enhancer activity, where the activity was higher in the x allele than in the X allele. Herrington et al. (2002) suggested that the P allele underlines a functional myb transcription factor-binding site that could alter the transcription, stability, or structure of the ESR1 transcript and the subsequent ESR1 protein.
There is also a possibility that ESR1 PvuII and XbaI polymorphisms may be in LD with disease susceptibility genes.
The difference in the associations across countries, even within the same ethnic group remains unexplained. This could be due to unknown environmental factors and not ethnicity but country-related genetic factors. It is also unclear why a weak association of these polymorphisms and AD was observed in men in particular, in the different populations analyzed. This could be due to different levels of production and the effects of estrogen among men and women. However, we cannot rule out the possibility of false-positive type I error, due to the small number of studies included in this meta-analysis. Therefore, further studies with a large sample size are recommended.
Our study has several limitations. First, heterogeneity and confounding factors might have distorted the analysis. Second, it would have been interesting to evaluate the association between ESR1 polymorphisms and clinical features of AD, but this was not possible because of the limited data.
In conclusion, this meta-analysis shows that the ESR1 PvuII polymorphism is associated with AD susceptibility in males, and that ESR1 XbaI polymorphism is associated with AD risk in the Japanese population. In addition, the PP/XX haplotype is associated with AD susceptibility in the Chinese population. These data support that the ESR1 PvuII and XbaI polymorphisms play a role in susceptibility to AD.
